Holen Sie sich die Stockscreener-App
1,142.85
0.61%
-7.00
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Eli Lilly stock after-hours at EUR 1,028.40: plus 0.07 percent versus prior close - AD HOC NEWS
‘India’s biotech ecosystem holds tremendous promise’: Eli Lilly CEO - The Economic Times
How Eli Lilly Just Extended Its Lead in the Weight-Loss Drug Market - Barron's
Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal - AOL.com
Eli Lilly's Once-Daily Weight Loss Pill Orforglipron Shows Significant Reduction in Heart Disease Risk - Benzinga
Eli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says - marketscreener.com
Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
Foghorn lays off 40% of staff after Lilly collaboration ends - biospace.com
Analyst recommendations: Alphabet, Amazon, Micron, Tesla, Eli Lilly… - marketscreener.com
BMO reiterates Eli Lilly stock Outperform on TRIUMPH-2 data By Investing.com - Investing.com UK
Eli Lilly presents Foundayo data. Eli Lilly and Company stock falls 1.18 percent - AD HOC NEWS
Why Is Eli Lilly (NYSE:LLY) Suddenly a Must-Watch Healthcare Stocks Stock Today? - Kalkine Media
Eli Lilly's Foundayo Shows Promising Results in Reducing Diabetes and Cardiovascular Risks (LLY) - GuruFocus
Eli Lilly's Foundayo Shows Major Diabetes Risk Reduction; LLY St - GuruFocus
Foghorn stock down as Lilly exits collaboration (FHTX:NASDAQ) - Seeking Alpha
Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease - PR Newswire
Eli Lilly stock pre-market at EUR 1,025.00: minus 0.26 percent - AD HOC NEWS
Eli Lilly's Ebglyss Phase 3 Success Highlights Growth Potential for LLY - GuruFocus
Eli Lilly Loses Full Fed. Circ. Bid To Nix Teva's $177M IP Win - Law360
Lilly combo drug cuts weight up to 23% in trial - Briefs Finance
Eli Lilly's Foundayo Shows Cardiovascular Benefits in Phase 3 Tr - GuruFocus
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study - PR Newswire
Experimental Lilly combination drug tops Zepbound in weight-loss trial - reuters.com
Missed Out On The Eli Lilly & Novo Nordisk GLP-1 Boom? These 7 Stocks Could Benefit Next! - Stocks Down Under
Doctors condemn big pharma's move to dispense GLP-1s to your door - ABC News & Headlines – Australian Broadcasting Corporation
Lilly's retatrutide GLP-1 delivers average weight loss of 50 pounds - USA Today
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo - Fierce Biotech
Eli Lilly Data Shows Retatrutide Promotes Weight Loss Over Eighty Weeks - Benzinga
Eli Lilly's EloraTZP Shows Promising Weight Loss Results in Mid-Stage Trial (LLY) - GuruFocus
Eli Lilly unveils compelling Phase 2b results for its EloraTZP combination - marketscreener.com
Eli Lilly (LLY) Reports Promising Phase 2b Results for EloraTZP in Obesity and Type 2 Diabetes - GuruFocus
Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial - statnews.com
Eli Lilly (LLY) Reports Promising Phase 2b Trial Results for Elo - GuruFocus
Eloralintide: Eli Lilly's New Obesity Treatment Shows Promising Results - GuruFocus
Eli Lilly stock rises on striking 23% weight loss in drug combo trial - Investing.com
What's Behind Eli Lilly's (NYSE:LLY) Big Moment in Healthcare Stocks Today? - Kalkine Media
Tirzepatide or Semaglutide? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli - Benzinga
Lilly Drug Combo Spurs Record Weight Loss in Diabetes Study - Bloomberg.com
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes - Eli Lilly
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial - cnbc.com
Eli Lilly's Ebglyss Shows Strong Phase 3b Results for Atopic Der - GuruFocus
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - GlobeNewswire Inc.
Is Eli Lilly and Co (LLY) a Bargain After 0.0% Drop? GF Value Sa - GuruFocus
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Eli Lilly (LLY) Reports Strong TRIUMPH-2 Trial Results for Retat - GuruFocus
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why. - The Motley Fool
Eli Lilly’s Experimental Weight-Loss Drug Shows Promising Results - yahoo.com
Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro - reuters.com
Wegovy or Zepbound? Eli Lilly Shows Zepbound Outperforms Wegovy in New Weight Loss Data - yahoo.com
Lilly Says Higher-Dose Zepbound Just Widened Its Lead Over Wegovy - Yahoo Finance
Lilly touts Foundayo advantage over Novo's Ozempic pill in diabetes analysis - reuters.com
Eli Lilly's Zepbound Shows Superior Weight Loss vs Wegovy HD, Bo - GuruFocus
Eli Lilly Launches Global Push to Expand Weight-Loss and Diabetes Drug Access in Lower Income Countries - Benzinga
Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison - PR Newswire
Eli Lilly Upgraded, Intel Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Eli Lilly's Foundayo Shows Superior Weight Loss Results; LLY Sto - GuruFocus
Barclays Keeps Their Buy Rating on Eli Lilly & Co (LLY) - theglobeandmail.com
Eli Lilly & Co Lobbyists, 2011 - OpenSecrets
Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison - Eli Lilly
Lilly Eyes Bigger Acquisitions After $7.8B Deal - Briefs Finance
Eli Lilly CEO Eyes Larger Acquisitions in Key Health Areas, Tick - GuruFocus
Lilly CEO Eyes Bigger ‘White Space’ Deals After A Record 2026 Shopping Spree - Stocktwits
Lilly CEO Eyes Bigger Deals in Hunt for Pharma’s ‘White Spaces’ - Bloomberg.com
1.02%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):